Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prospective, Comparative, Randomized, Controlled Trial on the Efficacy of the Treatment of Gastroesophageal Reflux Infant With Magnesium Alginate
Brief Summary: The results on the efficacy of the formulations based on alginic acid are controversial. Corvaglia et al demonstrated a significant reduction in reflux episodes in preterm infants by evaluation with pH-impedance analysis. This study concludes that the use of alginic acid reduces the acidity of the gastroesophageal reflux (GER) and has a non-systemic effect and a lesser presence of side effects compared to the use of H2-receptor antagonist(H2RA) and proton pump inhibitor (PPI).


Options:
A: Inclusion Criteria:

* Endoscopically proven GERD diagnosed within 6 months before study entry.
* Weight must be equal to or over 8.3 kg; for subjects 6 years or greater, weight must be equal to or under 25 kg

Exclusion Criteria:

* History of GI disorders, ie, unrepaired tracheal esophageal fistula, GI malabsorption, Eosinophilic esophagitis
* Subjects 6-11 years old unable to swallow tablets
B: Inclusion Criteria:

* Patients' parents/guardians must provide written informed consent prior to the execution of any study-related procedures.
* Patients who are able to comprehend their involvement in a clinical study, including risks and benefits, (typically ≥6 years of age) must have assent documented by study personnel prior to any study-related procedures.
* Patients must be diagnosed with endoscopically proven GERD by the investigator during the screening period or have a previous (within 2 weeks prior to Visit 1) diagnosis of erosive esophagitis by endoscopy and are candidates for PPI therapy.

Exclusion Criteria:

* Patients who have used a proton pump inhibitor within 14 days prior to randomization, including over-the-counter omeprazole.
* Patients who have used any prescription or over-the-counter (OTC) treatment (other than proton pump inhibitors) for symptoms of GERD, such as histamine 2 receptor antagonists or prokinetics, within 72 hours prior to randomization.
* Patients with a known hypersensitivity, allergy, or intolerance to any component of esomeprazole or omeprazole.
C: Inclusion Criteria:

* Age \< 1 year
* Suggestive symptoms of gastroesophageal reflux (I-GERQ score \> 7)
* Absence of clinical evidence of allergy to cow milk protein or other allergic disorder
* No previous intake of thickened formulas, acid suppressants or drugs
* All parents or guardians must sign a document of informed consent
* Patients affected by chronic disease
* Patients affected by hepatic or renal diseases
* Patients affected by cardiac diseases

Exclusion Criteria:

* Patients affected by chronic disease
* Patients affected by hepatic or renal diseases
* Patients affected by cardiac diseases
* Inability or unwillingness to give informed consent
* Patients wth severe neurologic disease
* Patients affected by cow milk protein allergy
* Previous or ongoing intake of thickened formulas, acid suppressants or drugs
D: Inclusion Criteria:

* History of at least 1 Gastroesophageal Reflux Disease (GERD) symptom within 3 months of screening
* Positive esophagogastroduodenoscopy
* Signed informed consent
* Female patients (if menstruating) must be practicing birth control

Exclusion Criteria:

* Patients with history of esophagitis
* Patients who have milk protein allergy
* Patients who have taken Proton Pump Inhibitors or H2-blockers within 3 days
* Patients who have taken sucralate or any medication that affects gastrointestinal motility
* Patients with H. pylori
* Patients with lab values outside the normal age appropriate range
* Patients who have participated in another trial within 30 days before screening
* Patients with allergies to Proton Pump Inhibitors

Answer: C